Literature DB >> 15018594

Is omapatrilat a novel therapy of the past rather than the future?

Tsung O Cheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15018594     DOI： 10.2165/00003495-200464060-00007

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  4 in total

1.  Acronyms of cardiologic trials--2002.

Authors:  Tsung O Cheng; Desmond Julian
Journal:  Int J Cardiol       Date:  2003-10       Impact factor: 4.164

2.  Omapatrilat may indeed not be much superior (OMINOUS).

Authors:  Tsung O Cheng
Journal:  Int J Cardiol       Date:  2003-09       Impact factor: 4.164

Review 3.  Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.

Authors:  Reza Tabrizchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Omapatrilat--the story of Overture and Octave.

Authors:  Andrew J S Coats
Journal:  Int J Cardiol       Date:  2002-11       Impact factor: 4.164
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.